Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashok Yanamadala

Psychiatry Saint Louis, MO Medical Doctor

NPI 1558418301 CMS profile 206244

4121 Union Rd Ste 201, Saint Louis, MO 63129

Open in the dashboard

General payments

$3,291

233 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashok Yanamadala of Saint Louis, MO is reported in the CMS Open Payments database as having received $3,291 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15 1
2023 General $148 11
2022 General $1,429 97
2021 General $579 36
2020 General $301 21
2019 General $820 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashok Yanamadala
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Ashok Yanamadala were reported at $15. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Ashok Yanamadala Psychiatry median Middle half National median
2019 $820 $184 $59–$605 $163
2020 $301 $119 $36–$372 $114
2021 $579 $143 $43–$576 $132
2022 $1,429 $153 $50–$590 $149
2023 $148 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $15 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neos Therapeutics, LP $570 41 payments
  2. Sunovion Pharmaceuticals Inc. $515 43 payments
  3. ITI, Inc. $449 20 payments
  4. AbbVie, Inc. $364 25 payments
  5. Supernus Pharmaceuticals, Inc. $247 32 payments
  6. Otsuka America Pharmaceutical, Inc. $236 15 payments
  7. Lundbeck LLC $182 13 payments
  8. Vanda Pharmaceuticals Inc. $168 9 payments
  9. Alkermes, Inc. $157 8 payments
  10. Janssen Pharmaceuticals, Inc $110 7 payments
  11. Other $292 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,218 228 payments
  2. Education $73 5 payments
Products named General payments · program years 2019–2025
  1. LATUDA $515 43 payments
  2. CAPLYTA $449 20 payments
  3. Adzenys XR-ODT $383 26 payments
  4. VRAYLAR $348 24 payments
  5. QELBREE $247 32 payments
  6. REXULTI Psychiatry $236 15 payments
  7. COTEMPLA XR-ODT $187 15 payments
  8. REXULTI Psychiatry $182 13 payments
  9. HETLIOZ $168 9 payments
  10. FANAPT $168 9 payments
  11. Other $1,371 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

6,934

Median for Psychiatry: 574

Drug cost

$233,781

Median for Psychiatry: $27,624

Branded share of claims

19.6%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rexulti Brexpiprazole Brand 31 $47,003
Caplyta Lumateperone Tosylate Brand 12 $20,218
Trintellix Vortioxetine Hydrobromide Brand 39 $19,662
Lurasidone Hcl Generic 72 $18,834
Vraylar Cariprazine Hcl Brand 12 $17,080
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 405 $13,259
Quetiapine Fumarate Er Quetiapine Fumarate Brand 58 $11,333
Alprazolam Generic 1,170 $7,543
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 136 $6,803
Adderall Xr Dextroamphetamine/Amphetamine Brand 19 $5,511

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$43,056

Medicare's payments for the services billed

Medicare patients

124

Average age 60

Services billed

774

68 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 60%
Arthritis 36%
Diabetes 26%
COPD 23%
Ischemic heart disease 15%
Chronic kidney disease 14%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record